AUTHOR=Jiang Lingli , Tan Jingjie , Hao Yi , Wang Qi , Yan Xiaorui , Wang Dali , Tuo Li , Wei Zairong , Huang Guangtao 

TITLE=Isolation and Characterization of a Novel Myophage Abp9 Against Pandrug Resistant Acinetobacater baumannii

JOURNAL=Frontiers in Microbiology

VOLUME=11

YEAR=2020

URL=https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2020.506068

DOI=10.3389/fmicb.2020.506068

ISSN=1664-302X

ABSTRACT=<p><italic>Acinetobacter baumannii (A. baumannii)</italic> has emerged as one of the most troublesome pathogens in health care institutions. <italic>A. baumannii</italic> can cause a wide range of diseases in humans, including pneumonia and septicemia. Phage therapy has drawn great interest from medical researchers as a potential way to control infections by antibiotic-resistant <italic>A. baumannii</italic>. Using a pandrug-resistant clinical <italic>A. baumannii</italic> isolate AB<sub>ZY</sub>9 as an indicator, we isolated a lytic phage Abp9 from hospital sewage. Abp9 belongs to <italic>myoviridae</italic> family and shows a wider host range of 12%. Abp9 contains a linear double-stranded DNA genome of 44,820 bp with a G + C content of 37.69%. The Abp9 genome contains 80 open reading frames, but lacks any known virulence genes or lysogen-formation genes. In a systemic <italic>A. baumannii</italic> infection mouse models, Abp9 treatment showed good therapeutic effects. We have also observed an excellent lytic activity against <italic>A. baumannii</italic> in biofilm form of growth <italic>in vitro</italic>. All of these suggest that Abp9 is a good candidate for the phage therapy against drug-resistant <italic>A. baumannii</italic> infections.</p>